Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Fineline Cube Jul 9, 2026
Company Deals

Xenovector and Jilin University Launch Strategic Partnership to Advance Gene-Edited Pig Organ Transplantation from Breakthrough to Affordable Healthcare

Fineline Cube Jul 9, 2026
Company Deals

Zhejiang Hisun Pharmaceutical and Tigermed Forge Strategic Alliance to Create End-to-End Innovative Drug Development Pipeline

Fineline Cube Jul 9, 2026
Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s National Health Commission Unveils 2026 Essential Medicines List, Adding 116 New Drugs with Full Insurance Coverage

Fineline Cube Jul 9, 2026
Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Fineline Cube Jul 9, 2026
Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Fineline Cube Jul 9, 2026
Company Deals

Astellas Pharma Acquires Propella Therapeutics for $175 Million to Boost Prostate Cancer Treatment

Fineline Cube Nov 16, 2023

Japan’s Astellas Pharma (TYO: 4503) has announced the negotiation of a purchase agreement for US...

Company Deals

Novartis Acquires HDAC6 Inhibitor CKD-510 from CKD Pharmaceutical in a $1.31 Billion Deal

Fineline Cube Nov 16, 2023

Swiss pharmaceutical major Novartis (NYSE: NVS) announced last week that it has struck a deal...

Company Drug

China’s NMPA Accepts EOC Pharma Group’s Filing for Vascepa (Icosapent Ethyl) for Review

Fineline Cube Nov 15, 2023

The China-based EOC Pharma Group has achieved a significant milestone with the National Medical Products...

Company Deals

Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition

Fineline Cube Nov 15, 2023

The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer...

Company

Merck KGaA Outlines Expansion Plans for US Healthcare Market with Anticipated 2025 Drug Launches

Fineline Cube Nov 15, 2023

Germany’s Merck KGaA (ETR: MRK), a leading player in the global pharmaceutical industry, has this...

Company Deals

Hubei Topgene Biotechnology and Shanghai Genechem Partner on Drug Toxicological Safety and Clinical Research

Fineline Cube Nov 15, 2023

Hubei Topgene Biotechnology Co., Ltd, a China-based biotechnology company, has entered into a partnership with...

Company Drug

EMA’s CHMP Issues Positive Opinion for Roche’s Tecentriq SC Subcutaneous Formulation

Fineline Cube Nov 15, 2023

The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA)...

Company Deals

PRECEDO Secures Over RMB 100 Million in Financing to Build Living Primary Cancer Cell Bank

Fineline Cube Nov 15, 2023

PRECEDO, a leading cell engineering specialist headquartered in Hefei, has reportedly secured more than RMB...

Company Deals

Yantai Dongcheng Pharmaceutical and Eckert & Ziegler Form Joint Venture for Medical Isotopes

Fineline Cube Nov 15, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a China-based pharmaceutical company, is poised to...

Policy / Regulatory

China’s National Allied Procurement Office Announces VBP Tender for Medical Consumables and 3D Printing Products

Fineline Cube Nov 15, 2023

The National Allied Procurement Office has released a notification outlining plans for a volume-based procurement...

Company Medical Device

Sansure Biotech Secures CE IVDR Certifications for Chemiluminescence Analyzers in the EU

Fineline Cube Nov 15, 2023

China-based molecular diagnostics specialist, Sansure Biotech Inc., (SHA: 688289), has announced that it has received...

Company Deals

Huadong Medicine Co., Ltd Secures Partnership and Commercial Rights for Yuyan’s Botulinum Toxin

Fineline Cube Nov 15, 2023

China-based Huadong Medicine Co., Ltd (SHE: 000963) has entered into an equity investment and partnership...

Company Deals Digital Hospital

Zeiss Group and China’s Healthcare Cloud Collaborate on Ophthalmic Services in China

Fineline Cube Nov 15, 2023

Germany-based Zeiss Group, a leader in optical systems and optoelectronic product manufacturing, has entered into...

Company Drug

Eli Lilly’s Donanemab on Track for Priority Review in China for Early-Stage Alzheimer’s

Fineline Cube Nov 15, 2023

The China’s Center for Drug Evaluation (CDE) website has indicated that Eli Lilly’s (NYSE: LLY)...

Company

CASI Pharmaceuticals Reports Q3 2023 Results with Mixed Fortunes and Positive Developments

Fineline Cube Nov 15, 2023

China-based CASI Pharmaceuticals Inc., (NASDAQ: CASI) has unveiled its financial results for the third quarter...

Company Deals

Novartis Pharma AG Partners with Legend Biotech Corp. for CAR-T Therapies in $1.1 Billion Deal

Fineline Cube Nov 14, 2023

China-based Legend Biotech Corp., (NASDAQ: LEGN) has secured a second multinational partnership for its chimeric...

Company Deals R&D

Nona Biosciences Partners with GeneQuantum Healthcare to Advance Drug Conjugate Discovery

Fineline Cube Nov 14, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), which operates across the...

Company Deals

Autobio Diagnostics Expands Strategic Partnership with Guorun Medical Supply Chain Services

Fineline Cube Nov 14, 2023

China-based Autobio Diagnostics Co., Ltd (SHA: 603658) has announced a strategic partnership with Guorun Medical...

Company Digital

BMS Secures ORM-6151 for Acute Myeloid Leukemia Treatment with Orum Therapeutics Deal

Fineline Cube Nov 14, 2023

Bristol Myers Squibb (BMS; NYSE: BMY) has made a significant move in the field of...

Company Drug

Bayer Withdraws Aliqopa FDA Filing Following Missed Phase III Endpoint

Fineline Cube Nov 14, 2023

Germany-based pharmaceutical major Bayer (ETR: BAYN) has announced its decision to withdraw the filing for...

Posts pagination

1 … 470 471 472 … 693

Recent updates

  • Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients
  • Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs
  • Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial
  • Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST
  • Changchun High & New Technology’s Subsidiary GenSci Secures NMPA IND Acceptance for GenSci148, First-in-Class VEGF Multi-Blocker for Retinal Vascular Diseases
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Astellas Pharma Submits BLA to China NMPA for PADCEV-Keytruda Combination in Muscle-Invasive Bladder Cancer, Showing 60% Reduction in Recurrence Risk for Cisplatin-Ineligible Patients

Company Drug

Jiangsu Aidea Pharmaceutical Receives NMPA Clinical Trial Approval for ADC119, China’s First Domestic Complete HIV Regimen Combining Novel NNRTI with Established NRTIs

Company Drug

Shenyang Xingqi Pharmaceutical Reports Positive Phase 2 Results for SQ-22031 Eye Drops in Neurotrophic Keratitis, Advances to Pivotal Phase 3 Trial

Company Deals

Sino Biopharmaceutical Secures Exclusive Global Rights to Yikexin TRACE Treatment Series Through CTTQ Partnership with Beijing CIST

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.